Evidence map›Paper›PMID 36815376›Full record

ArticleActa biochimica et biophysica Sinica2023

A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway.

Bibo Zhang, Bo Li, Yongsheng Xie, Shuaikang Chang, Zhijian Xu, Huifang Hu, Gege Chen, Ting Zhang, Jun He, Xiaosong Wu and 7 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Bibo ZhangDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Bo LiCAS Key Laboratory of Receptor Research, Stake Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Yongsheng XieDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Shuaikang ChangDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Zhijian XuCAS Key Laboratory of Receptor Research, Stake Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Huifang HuCAS Key Laboratory of Receptor Research, Stake Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Gege ChenDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Ting ZhangDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Jun HeDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Xiaosong WuDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Huabin ZhuDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Weiming LaiDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Dongliang SongDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Ying LuDepartment of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo 315000, China.
Xinyan JiaDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Weiliang ZhuCAS Key Laboratory of Receptor Research, Stake Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Jumei ShiDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Shanghai East Hospital · CNShanghai Tenth People's Hospital · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM), the second most common haematological malignancy, is currently incurable because patients often develop multiple drug resistance and experience subsequent relapse of the disease. This study aims to identify a potential therapeutic agent that can counter bortezomib (BTZ) resistance in MM. DCZ0358, a novel alkaloid compound, is found to exert potent cytotoxic effects against BTZ-resistant MM cells

Indexed as

AlkaloidsAntineoplastic AgentsMultiple MyelomaApoptosisBortezomibCell Line, TumorCell ProliferationHumansIsoquinolinesJanus Kinase 2OxazolesSTAT3 Transcription FactorAlkaloidsAntineoplastic AgentsBortezomibDCZ0358IsoquinolinesJAK2 protein, humanJanus Kinase 2OxazolesSTAT3 protein, humanSTAT3 Transcription Factorapoptosiscell cycle arrestDCZ0358JAK2/STAT3 pathwaymultiple myeloma

Identifiers

PMID36815376
PMCPMC10157528
OpenAlexW4319335259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.